XML 80 R37.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Significant Contracts (Narrative) (Details) $ in Millions |  | 12 Months Ended
--- | --- | ---
Oct. 01, 2018 item | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($)
Clinical Collaboration Agreement [Member] | The University of Texas MD Anderson Cancer Center [Member] |  |  |
Supply Commitment [Line Items] |  |  |
Term of agreement | 3 years |  |
Number of clinical studies conduct | item | 4 |  |
Clinical Collaboration Agreement [Member] | The University of Texas MD Anderson Cancer Center [Member] | Maximum [Member] |  |  |
Supply Commitment [Line Items] |  |  |
Number of patients enroll in clinical studies | item | 170 |  |
Daiichi Sankyo [Member] |  |  |
Supply Commitment [Line Items] |  |  |
Future milestone payments payable | $ |  | $ 10.0 |
Period for which royalties will be paid following first commercial sale of licensed products |  | 10 years |
Notice period for termination of license by the entity for technical, scientific, efficacy, safety, or commercial reasons |  | 6 months |
Notice period for termination of license after launch of a sapacitabine-based product by the entity, or by either party for material default |  | 12 months |
Notice period for right of first refusal if third party to be appointed to develop or commercialize a sapacitabine-based product in Japan |  | 60 days |
Milestones earned | $ |  | $ 0.0 | $ 0.0

X
- Definition Represent the number of clinical studies conduct. + References No definition available. + Details
Name: | cycc_ConductClinicalStudies
Namespace Prefix: | cycc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of milestones earned during the period per the terms of the license agreement. + References No definition available. + Details
Name: | cycc_LicenseAgreementMilestonesEarned
Namespace Prefix: | cycc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The required notification period for right of first refusal if entity elects to appoint a third party to develop or commercialize a sapacitabine-based product in Japan. + References No definition available. + Details
Name: | cycc_LicenseAgreementNoticePeriodForRightOfRefusalForThirdPartyAppointmentToDevelopOrCommercializeSapacitabineBasedProductInJapan
Namespace Prefix: | cycc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the notice period for the termination of license after a launch of a sapacitabine-based product, or by either party for material default. + References No definition available. + Details
Name: | cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault
Namespace Prefix: | cycc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period for which royalties will be paid following the first commercial sale of licensed products in the country. + References No definition available. + Details
Name: | cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry
Namespace Prefix: | cycc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The potential future milestone payments required to be made under certain contractual agreements. + References No definition available. + Details
Name: | cycc_LicenseAgreementPotentialFutureMilestonePayments
Namespace Prefix: | cycc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the notice period for the termination of license by the reporting entity for technical, scientific, efficacy, safety, or commercial reasons. + References No definition available. + Details
Name: | cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason
Namespace Prefix: | cycc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represent the number of patients enroll in clinical studies. + References No definition available. + Details
Name: | cycc_PatientsEnrollInClinicalStudies
Namespace Prefix: | cycc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents term of agreement. + References No definition available. + Details
Name: | cycc_TermOfAgreement
Namespace Prefix: | cycc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SupplyCommitmentLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cycc_ClinicalCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cycc_MdAndersonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=cycc_DaiichiSankyoCompanyLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |